1-2 of 2
Miranda Harris
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia

Free
Meghan Thompson, Anthony Mato, Andrew Zelenetz, Jae Park, Mark Geyer, Andriy Derkach, David Nemirovsky, Deborah Stephens, Catherine Coombs, Prioty Islam, Christopher Jensen, Lorenzo Falchi, Lia Palomba, Anita Kumar, Gilles Salles, Eytan Stein, Jennifer Lue, Lauren Nogan, Bejal Kikani, Ryan Sutterby, Thu Quynh Nguyen, Alexandra Allen, Sumathy Sudhir, Gail Panton, Victoria Duffy, Dianna Tyznar, Jamila Brutus, Tenzin Nyima, Anmol Shah, Dhara Soni, Michael Silvestrone, Monica Shah, Miranda Harris, Megha Karnam, Claire Hutzler, Kevin David, Aaron Goldberg, Stephen Fleming, Giovanni Diaz, Habib Hamidi, Bita Fakhri, Lindsey Roeker
Journal: Blood
Blood (2025) 146 (Supplement 1): 3902.
https://doi.org/10.1182/blood-2025-3902
Published: 2025
Journal Articles

A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia

Free
Meghan Thompson, Anthony Mato, Lia Palomba, Lori Leslie, Andriy Derkach, David Nemirovsky, Prioty Islam, Mark Geyer, Philip Caron, Aaron Goldberg, Anita Kumar, Alison Moskowitz, Jennifer Lue, Colette Owens, Gilles Salles, Eytan Stein, Raphael Steiner, Pallawi Torka, Lori Dahncke, Emily Ordona, Mashiyate Meem, Claire Hutzler, Miranda Harris, Monica Shah, Megha Karnam, Lauren Nogan, Caitlin Maloney, Anmol Shah, Tenzin Nyima, Colleen Dorsey, Kate Doyle, Jennifer Howgate-Klingaman, Jamila Brutus, Dianna Tyznar, Anna Lincke, Rick Wray, Tatyana Feldman, Andrew Zelenetz, Lindsey Roeker
Journal: Blood
Blood (2025) 146 (Supplement 1): 5676.
https://doi.org/10.1182/blood-2025-5676
Published: 2025